Advances in Cancer Research - 1st Edition - ISBN: 9780128002490, 9780128003176

Advances in Cancer Research, Volume 121

1st Edition

Editors: Kenneth D. Tew Paul B. Fisher
eBook ISBN: 9780128003176
Hardcover ISBN: 9780128002490
Imprint: Academic Press
Published Date: 1st June 2014
Page Count: 426
Sales tax will be calculated at check-out Price includes VAT/GST
30% off
30% off
30% off
30% off
30% off
30% off
30% off
30% off
30% off
30% off
30% off
30% off
Price includes VAT/GST
× DRM-Free

Easy - Download and start reading immediately. There’s no activation process to access eBooks; all eBooks are fully searchable, and enabled for copying, pasting, and printing.

Flexible - Read on multiple operating systems and devices. Easily read eBooks on smart phones, computers, or any eBook readers, including Kindle.

Open - Buy once, receive and download all available eBook formats, including PDF, EPUB, and Mobi (for Kindle).

Institutional Access

Secure Checkout

Personal information is secured with SSL technology.

Free Shipping

Free global shipping
No minimum order.

Table of Contents

  • Chapter One: Glial Progenitors as Targets for Transformation in Glioma
    • Abstract
    • 1 Introduction
    • 2 Glial Cell Lineages
    • 3 Glioma Subgroups and Cell of Origin
    • 4 H3F3A Mutations Drive Gliomagenesis in Separate Brain Regions
    • 5 Gliomagenesis and Mutations in Isocitrate Dehydrogenase Genes
    • 6 Proneural-to-Mesenchymal Transition in Glioma
    • 7 Relationship Between GSCs and Glial Progenitors
    • 8 Targeted Therapy in Glioma
    • 9 Concluding Remarks and Future Perspectives
    • Acknowledgments
  • Chapter Two: Therapeutic Cancer Vaccines
    • Abstract
    • 1 Introduction
    • 2 Cancer Vaccine Targets
    • 3 Spectrum of Current Therapeutic Cancer Vaccine Platforms
    • 4 Animal Models to Evaluate Cancer Vaccines: Pros and Cons
    • 5 Types of Immunotherapy
    • 6 The Importance of Antigen Cascade in Vaccine-Mediated Therapeutic Responses
    • 7 TRICOM-Based Vaccines: Clinical Studies
    • 8 Prostate Cancer Clinical Trials
    • 9 Vaccine Combination Therapies
    • 10 Combination Therapies—Preclinical Studies
    • 11 Influence of the Tumor Microenvironment and Immunosuppressive Factors
    • 12 Vaccine Combination Therapies—Clinical Studies
    • 13 Biomarkers
    • 14 Vaccine Targets Involved in Tumor Progression and Drug Resistance
    • 15 Concluding Remarks
  • Chapter Three: IKK/Nuclear Factor-kappaB and Oncogenesis: Roles in Tumor-Initiating Cells and in the Tumor Microenvironment
    • Abstract
    • 1 Introduction
    • 2 Tumor Microenvironment
    • 3 TICs/Cancer Stem Cells
    • 4 Conclusions
    • Acknowledgments
  • Chapter Four: The Rb–E2F Transcriptional Regulatory Pathway in Tumor Angiogenesis and Metastasis
    • Abstract
    • 1 Introduction
    • 2 Rb–E2F Pathway in Angiogenesis
    • 3 Rb–E2F Pathway and Tumor Metastasis
    • 4 Conclusions
    • Acknowledgments
  • Chapter Five: ATP-Dependent Chromatin Remodeling Complexes as Novel Targets for Cancer Therapy
    • Abstract
    • 1 Introduction—The Importance of Gene Expression to Cancer Biology
    • 2 An Overview of Epigenetic Regulatory Mechanisms
    • 3 ATP-Dependent Chromatin Remodeling
    • 4 Evidence of Widespread Roles for Chromatin Remodeling in Human Cancer
    • 5 A Review of the Literature on Chromatin Remodeling and Cancer
    • 6 Therapeutic Potential of Chromatin Remodeling Complexes in Human Cancer
    • 7 Concluding Remarks
    • Acknowledgments
  • Chapter Six: Diffuse Intrinsic Pontine Gliomas: Treatments and Controversies
    • Abstract
    • 1 Introduction
    • 2 Diagnosis
    • 3 Historical Perspectives
    • 4 Current Treatments
    • 5 Recent Developments
    • 6 Conclusion
  • Chapter Seven: In Vivo Modeling of Malignant Glioma: The Road to Effective Therapy
    • Abstract
    • 1 Introduction
    • 2 Malignant Glioma
    • 3 Notable Aberrant Signaling Pathways in Malignant Glioma
    • 4 Molecular Classification of GBM
    • 5 Progression of Glioblastoma
    • 6 Introduction to Animal Modeling in Glioma
    • 7 Non-Mammalian Models of Glioma
    • 8 Mammalian Models of Glioma
    • 9 Conclusions and Future Perspectives
    • Acknowledgments
  • Chapter Eight: Genetically Engineered Mice as Experimental Tools to Dissect the Critical Events in Breast Cancer
    • Abstract
    • 1 Introduction
    • 2 Modeling Various Aspects of Human Breast Cancer Initiation and Progression in Mice
    • 3 Developing Novel Therapeutics and Imaging Techniques Using Transgenic Animals
    • 4 Conclusions and Future Perspectives
    • Acknowledgments
  • Chapter Nine: Life is Three Dimensional—As In Vitro Cancer Cultures Should Be
    • Abstract
    • 1 3D Cell Culture Methods and Scaffolding Materials
    • 2 Cell Morphology
    • 3 Cell Proliferation
    • 4 Cell Viability and Drug Metabolism Effects
    • 5 Cell Response to External Stimuli
    • 6 Differentiation
    • 7 Cancer Stem Cells
    • 8 Gene and Protein Expression
    • 9 Future Perspectives
  • Index


Advances in Cancer Research provides invaluable information on the exciting and fast-moving field of cancer research. Here, once again, outstanding and original reviews are presented on a variety of topics.

Key Features

  • Provides information on cancer research
  • Outstanding and original reviews
  • Suitable for researchers and students


Researchers and students in the basic and clinical sciences of cancer biology and oncology, plus related areas in genetics, immunology, pharmacology, cell biology, and molecular biology.


No. of pages:
© Academic Press 2014
Academic Press
eBook ISBN:
Hardcover ISBN:


Praise for the Series: "Excellent, highly informative, in-depth reviews... expertly written, up-to-date, and well-referenced." - JOURNAL OF MEDICINAL CHEMISTRY

Ratings and Reviews

About the Editors

Kenneth D. Tew Editor

Professor & Chairman, Dept of Cell & Molecular Pharmacology John C. West Chair of Cancer Research, Medical University of South Carolina, USA

The Tew laboratory maintains an interest in using redox pathways as a platform to develop therapeutic strategies through drug discovery/development and biomarker identification. We interrogate how reactive oxygen and nitrogen species (ROS/RNS) impact cancer cells and develop novel drugs that impact on glutathione based pathways. Our research efforts have been integral to studies that have identified glutathione S-transferases (GST) as important in drug resistance, catalytic detoxification and as arbiters of kinase-mediated cell signaling events. In addition, we have been instrumental in defining how GSTP contributes to the process by which cells respond to ROS by selective addition of glutathione to specific protein clusters, so called S-glutathionylation. Each of these research areas has had broad impact on a number of cancer disciplines. Moreover, we have also been seminally involved in the Phase I to III clinical testing of three oncology drugs, Telcyta, Telintra and NOV-002. Other ongoing translational efforts have produced two ongoing clinical trials to measure the effectiveness of serum S-glutathionylated serine proteinase inhibitors as possible biomarkers for exposure to hydrogen peroxide mouthwashes and radiation.

Affiliations and Expertise

Department of Cell and Molecular Pharmacology, Medical University of South Carolina, USA

Paul B. Fisher Editor

Paul B. Fisher, M.Ph., Ph.D., is an accomplished molecular biologist investigating the mechanisms involved in cancer development and progression in order to define improved methods for cancer prevention, detection and therapy. Fisher pioneered a powerful technique to study gene expression in specific tissues or cell types known as subtraction hybridization, which he has used to identify genes involved in many important and medically relevant physiological processes including cancer, neurodegeneration and infectious diseases. Studies in his laboratory focus on understanding the molecular and biochemical reasons for cancer development with a specific focus on understanding how cancers spread, a process called metastasis. The ultimate aim is to use this collected knowledge to bring new, more effective prevention techniques, diagnostic approaches and therapies from the laboratory bench to the patient’s bedside. This is epitomized by his studies involving mda-7/IL-24, a gene that was discovered in his laboratory and has displayed significant clinical efficacy in a phase 1 clinical trial when injected directly into advanced cancers using a form of viral gene therapy. Using a novel cancer terminator virus, Ad.5/3-CTV, that is designed to replicate only within cancer cells while delivering the immune-modulating and toxic mda-7/IL-24 gene, Fisher and his clinical colleagues are developing a clinical trial in patients with glioblastoma multiforme, the most common and deadly form of brain cancer. Fisher has been consistently funded by the National Institutes of Health (NIH) over the past 35 years and is among the top 5 percent of NIH funded investigators during this period. He has published over 500 primary papers and reviews, served on numerous NIH study sections and government and private grant review panels and has over 55 issued patents. He is the recipient of multiple National Cancer Institute (NCI) Program Project Grants; investigator initiated R01 grants from the NIH, NCI and National Institute of General Medical Sciences (NIGMS); private foundation grants from the National Foundation for Cancer Research and the Samuel Waxman Cancer Research Foundation; and an Institutional Research and Academic Career Development Award from the NIH focusing on preparing students from groups underrepresented in the sciences for research careers. Fisher is Professor and Chair of the Department of Human and Molecular Genetics at the Virginia Commonwealth University (VCU) School of Medicine, Founding Director of the VCU Institute of Molecular Medicine and Thelma Newmeyer Corman Chair in Cancer Research and co-leader of the Cancer Molecular Genetics research program at VCU Massey Cancer Center.

Affiliations and Expertise

VCU Institute of Molecular Medicine, VA, USA